Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P16870
UPID:
CBPE_HUMAN
Alternative names:
Carboxypeptidase H; Enkephalin convertase; Prohormone-processing carboxypeptidase
Alternative UPACC:
P16870; A8K4N1; B3KR42; B4DFN4; D3DP33; Q9UIU9
Background:
Carboxypeptidase E (CPE), also known as Carboxypeptidase H or Enkephalin convertase, plays a crucial role in the sorting and processing of prohormones. It directs prohormones to the regulated secretory pathway and acts as a prohormone processing enzyme in neuro/endocrine cells, removing dibasic residues from peptide hormone precursors.
Therapeutic significance:
CPE is implicated in BDV syndrome, an autosomal recessive disorder characterized by obesity, intellectual disability, and hypogonadotropic hypogonadism. Understanding the role of Carboxypeptidase E could open doors to potential therapeutic strategies for BDV syndrome and related endocrine disorders.